Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: 8 - Caught on Camera

Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive

MarketBeat

Stock market today: Asian shares trade mixed after drops for Big Tech leave Wall Street mixed

Asian shares are mixed after gains for oil-and-gas producers helped offset drops for Nvidia and other Big Tech companies on Wall Street

The Independent UK

Largest ever protein study set to revolutionise cancer and dementia tests

Tens of millions of pounds in investment is being provided by the group of firms which includes AstraZenecaa and Pfizer

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

World’s largest proteins study ‘invaluable’ for understanding disease – experts

The scaled-up project is backed by a consortium of 14 pharmaceutical firms.

Evening Standard

Top 3 Discounted Dividend Stocks for 2025 That Could Skyrocket Your Portfolio

These three companies are leaders in their field, have a long history of increasing their dividends, and the stocks trade at a discount.

Barchart

Johnson & Johnson's Quarterly Earnings Preview: What You Need to Know

Johnson & Johnson is poised to release its fiscal fourth-quarter earnings this month, and analysts project a double-digit profit decline.

Barchart

‘I felt betrayed’: Woman blames cancer diagnosis on talcum powder use

Exclusive: Jane Campbell is one of thousands of women in the UK planning legal action against one of the world’s largest pharmaceutical firms over alleged links between talc and cancer

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Man sues Johnson & Johnson for $25m claiming talcum powder killed his wife

The lawsuit, filed in Maine, claims Cynthia Cartwright ingested asbestos while using the product, Pecos River Talc, which is a subsidiary of the pharmeceutical giant

The Independent UK

Pharmaceutical giant sued over 'ineffective' cold drugs

Pharmaceutical giant Johnson & Johnson is facing a class action concerning cold and flu medication known to be "ineffective".

AAP

Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies

Bridgewater Associates, the world's biggest hedge fund, sold top AI-linked stocks like Nvidia, Alphabet, Microsoft, Amazon, and Johnson & Johnson.

Benzinga

Johnson & Johnson Risks UK Lawsuit Over Talc Cancer Claim

UK claimants announced Wednesday legal action against US pharmaceutical and cosmetics giant Johnson & Johnson, alleging that women diagnosed with cancers were exposed to asbestos in the company's talcum powder.

International Business Times

Thousands of women plan legal action over alleged links between talc and cancer

If the action goes ahead it is understood to be the first of its kind against Johnson & Johnson in the UK.

Evening Standard

Are Wall Street Analysts Predicting Johnson & Johnson Stock Will Climb or Sink?

Johnson & Johnson has struggled to keep up with the broader market over the past year, and analysts are cautiously bullish on its future potential.

Barchart

3 Highest-yielding Dividend Kings for Maximum Income and Stability

Looking for reliable yield? These three companies offer ever-increasing dividends and a lifetime of stability.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Johnson & Johnson's Q3 2024 Earnings: What to Expect

Johnson & Johnson is all set to announce its third-quarter results this month, and analysts are projecting double-digit earnings decline.

Top News

Johnson & Johnson Subsidiary Files For Bankruptcy For Third Time

Johnson & Johnson subsidiary files for bankruptcy to settle talc-related cancer lawsuits. Proposed billion settlement faces legal challenges.

Creative Bloq

How typography can make or break a brand

We speak to experts in the field of typography to learn how the right type can be the making of a brand — or its undoing.

StockNews.com

3 Healthcare Stocks With Strong Buy Ratings

The healthcare sector is proving to be a robust investment haven, particularly as it continues to evolve with groundbreaking technology and strong government support. Therefore, adding strong A-rated stocks like Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co. (MRK) could help garner significant returns. Read more….

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

'I'm on morphine patches every day': Woman still waiting for vaginal mesh removal four years later

‘I used to walk everywhere, but now I just potter around the house. I no longer walk to the shops,’ June Dunne tells Maya Oppenheim

Barchart

How High Can This Healthcare Stock Soar With Nvidia's Help?

Dividend King J&J can boost its MedTech business with Nvidia’s help.

Evening Standard

Women harmed by vaginal mesh in England get payout

The amount of the financial settlement has not been made public, although it is expected millions have been paid out

Barchart

This Dividend Aristocrat Just Had Its Best Day Ever After Earnings

This dividend aristocrat crushed Q2 earnings and issued strong guidance, and still has some fuel left in the tank for more growth.

The Independent UK

140 women win payouts for vaginal mesh complications

Women claimed the implants caused infection, bleeding, chronic pain, bladder and bowel perforations, and problems urinating

The Guardian - UK

140 women in England receive payout for vaginal mesh implant complications

Settlement from first successful group claim in England expected to total millions of pounds, but size of payments unknown

Salon

Big Pharma fought to keep prices high

Big Pharma exploited patent laws to stifle competition amid Medicare price negotiations, according to a new report

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.